Conclusion
The etiology of Peyronie’s disease has not been fully elucidated, but
the inflammatory process has an important place in the disease’s
physiopathology. The fact that the only drug that is licensed for the
acute phase of the disease is collagenase clostridium histolyticum, and
that the effectiveness of other previously-attempted methods has not
been fully proven, makes us predict that new treatment modalities will
be investigated in the future as well. Our study shows that
intralesional usage of low dose methylprednisolone is effective for
improving symptoms and signs during the active period of Peyronie’s
disease. Thus, it may lead to a more progressive transition of the
disease from the acute phase to the chronic phase, resulting in less
penile deformity and less subsequent complicated correctional surgeries
for affected patients.